Dr. Jack Cush reviews the news and journal articles from the past 2 weeks on RheumNow.com. This week reviews clinical associations with SS-A, a new biomarker for SSc-ILD and cancer screening for myositis patients.
29 pts w/ PsA Sine Psoriasis: 16F/13M, mean age 45 yrs w/
The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
Read Article
This poster reports key efficacy outcomes such as ASAS40 response at Week 16 and Week 52 for the overall population and in TNFi-naïve and TNFi-experienced patients. The poster also discusses patients treated with BKZ achieving low disease activity (LDA) based on the ASDAS scores, objective
Read Article
Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
There has been considerable debate whether
Read Article
Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.
Moreover, patients became increasingly less likely to see substantial symptom improvement
Read Article
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
Read Article
Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.
"Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs
Links:
Links:
Links:
BE COMPLETE is published, showing that bimekizumab (BMK), a selective dual inhibitor of interleukin (IL)-17F and IL-17A, results in superior improvement in both skin and joint outcomes in psoriatic arthritis (PsA) patients who have previously failed treatment with a tumour necrosis factor-α (
Read Article
Dr. Jack Cush reviews the best of 2022 in Rheumatology - highlights on new drug indications, breakthrough lupus therapies, new biosimilars and the multivitamin letdown.
Read Article
2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care.
Read Article
The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis,
Read Article
Links:
Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or
Read Article
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
A series of surveys were initated by the British Psoriatic Arthritis Consortium (BritPACT) and funded by the James Lind Alliance (JLA
Read Article
